Toxicology Services
LabGen provides advanced toxicology testing designed for accurate medication monitoring, comprehensive substance detection, and defensible clinical reporting. As a CLIA-certified high-complexity diagnostic laboratory serving providers nationwide, we deliver precise quantitative analysis supported by validated instrumentation and rigorous quality standards.
Our toxicology division is built on gold-standard LC-MS/MS (Liquid Chromatography–Tandem Mass Spectrometry) technology, ensuring exceptional sensitivity, analytical specificity, and reproducibility across every test panel.
Presumptive screening methods such as immunoassays may lack the specificity required for confident treatment decisions. Definitive LC-MS/MS testing eliminates cross-reactivity concerns and provides exact drug identification with quantitative concentration levels.
LabGen’s LC-MS/MS platform enables detection of a broad range of designer substances and emerging synthetic compounds that may not be detected through traditional screening methods.
48–72 Hours
Our laboratory workflows are optimized for efficiency without compromising analytical precision. Reliable turnaround supports treatment plan adjustments, compliance documentation, and ongoing medication monitoring.
Results are delivered through secure electronic reporting systems designed to integrate seamlessly into provider workflows.
LabGen combines advanced LC-MS/MS instrumentation, validated methodologies, responsive provider support, and reliable turnaround times to deliver trusted toxicology solutions nationwide.
Start Your Partnership With LabGenDefinitive testing uses LC-MS/MS technology to specifically identify and quantify drugs and metabolites with high analytical precision.
Presumptive tests provide preliminary results, while definitive LC-MS/MS testing confirms exact substances and provides quantitative concentration levels.
Results are typically reported within 48–72 hours.
Yes. All toxicology panels provide concentration-based reporting rather than simple presence/absence detection.
Yes. Panels can be structured around pain management, behavioral health, primary care, addiction medicine, and specialty practice needs.
Yes. Our LC-MS/MS platform detects many emerging synthetic compounds and drug analogs.
Quantitative confirmation and validated methodologies support documentation requirements and defensible reporting.
Yes. LabGen operates under CLIA certification, participates in CAP proficiency testing, and maintains HIPAA compliance.
Yes. Quantitative results assist providers in evaluating therapeutic adherence and treatment effectiveness over time.